Relevium Technologies Inc. a Health and Wellness portfolio company
listed on TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX” (the
“Company” or “Relevium”) announced today it is positioning itself
as an important player in the Colombian medical cannabis
market by cementing medical and research relationships in the
country in order to establish clinical validation programs for its
Endo Nutraceutical Supplements (ENS) and Oral Nutritional
Supplements.
On June 13th, 2019, the Company announced a
binding LOI to acquire LifeLine Pharma SAS, a binding agreement to
acquire the shares of Lifeline Pharma SAS, a Cali based cultivation
and extraction business in the burgeoning agro-pharma market in
Colombia. With a much lower cost of production, a robust commercial
and legal framework and a culture that is open to Phyto therapeutic
medicine, Colombia is quickly becoming a global center of medical
cannabis supply and it is forecasted that the Country will be
looking to supply as much as 44% of the World’s demand.
“This is a major strategic step in the
development of our Phyto therapeutic biopharma business” stated
Aurelio Useche, CEO of Relevium Technologies.
The Company’s subsidiary, Biocannabix Health
Corporation, is a vertically integrated medical cannabis company
with strategic positioning in three major markets: Canada, Latin
America and Europe.
The company’s operations in Montreal allows
Biocannabix to leverage leading edge scientific and research
platforms as well as government incentives in the province of
Quebec. The recent acquisition of LifeLine in Colombia allows the
company to leverage lower costs of cultivation and processing as
well as to manage its own genetics for the production of targeted
Phyto therapeutic formulations. Colombia, Canada and Germany
combined are central to the clinical validation program for the ENS
and ONS products that will be offered in all three markets.
JUNE 28TH CONFERENCE CALL DETAILS AND
REGISTRATION INSTRUCTIONS
As announced last week, Relevium will be hosting
a LATAM Strategy Conference Call. In order to register for the call
please use the following link. Once registered you will receive
your call instructions and you will be able to add the event to
your calendar.
Please Click:
https://zoom.us/meeting/register/71292b6aa9d728da4ac87b605f06faf5
About Relevium Technologies
Relevium is a publicly-traded company that
operates in the health and wellness industry, including legal
cannabis, with a primary focus on online distribution. The
principal business of the Company is the identification,
evaluation, acquisition and operations of brands and businesses in
the health and wellness markets and medical cannabis. The Company
pursues its business strategy through an acquisition and
partnership model in a holistic approach to encompass a wide range
of health and wellness consumer products. Relevium operates through
two wholly owned subsidiaries:
BGX E-Health LLC (BGX), based in Orlando,
Florida, markets dietary supplements, nutraceuticals, sports
nutrition and cosmeceuticals primarily through its Bioganix® brand
portfolio in the US and Europe. Relevium’s premium brands are sold
at some of the world’s largest retailers including such as
Walmart.com and Amazon.com.
Biocannabix Health Corporation (BCX), based in Montreal, Quebec,
is a biopharma nutraceutical company focused on delivering
pediatric endo-medicinal nutraceuticals for cannabinoid
therapy.
About Lifeline Pharma
Lifeline Pharma SAS is a privately owned vertically integrated
agro-pharma business dedicated to scientific research, grow,
extraction, production and export of medicinal grade cannabis
derivatives. Incorporated in Cali, Colombia, Lifeline leverages 150
years of organic agriculture located in Rozo, Valle del Cauca, in
the heart of the sugar cane enclave, only 7 minutes away from the
international airport and 10 minutes away from Cali, the third
largest city in the country.
Cautionary Note Regarding Forward-Looking
Statements
This release includes certain statements and
information that may constitute forward-looking information within
the meaning of applicable Canadian securities laws. All statements
in this news release, other than statements of historical facts,
including statements regarding future estimates, plans, objectives,
assumptions or expectations of future performance, including the
timing and completion of the proposed acquisitions, are
forward-looking statements and contain forward-looking information.
Generally, forward- looking statements and information can be
identified by the use of forward-looking terminology such as
"intends" or "anticipates", or variations of such words and phrases
or statements that certain actions, events or results "may",
"could", "should", "would" or "occur". Forward-looking statements
are based on certain material assumptions and analysis made by the
Company and the opinions and estimates of management as of the date
of this press release, including the assumptions that the Company
will be able to apply for and ultimately obtain an ACMPR licence,
the proposed business of Biocannabix will develop as anticipated,
that the Company will raise sufficient funds to develop the
Biocannabix business, and that the Company will obtain all
requisite regulatory approvals. These forward-looking statements
are subject to known and unknown risks, uncertainties and other
factors that may cause the actual results, level of activity,
performance or achievements of the Company to be materially
different from those expressed or implied by such forward-looking
statements or forward-looking information. Important factors that
may cause actual results to vary, include, without limitation, the
risk that the proposed business developments may not occur as
planned; the timing and receipt of requisite approvals and failure
to raise sufficient funds.
Although management of the Company has attempted
to identify important factors that could cause actual results to
differ materially from those contained in forward-looking
statements or forward-looking information, there may be other
factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove
to be accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward- looking
statements and forward-looking information. Readers are cautioned
that reliance on such information may not be appropriate for other
purposes. The Company does not undertake to update any
forward-looking statement, forward-looking information or financial
outlook that are incorporated by reference herein, except in
accordance with applicable securities laws. We seek safe
harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES
INC.
Aurelio UsechePresident and CEO
For more information about this press release: Tel:
+1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.comWebsite:
www.releviumtechnologies.comLike us on FacebookFollow us on
TwitterFollow us on LinkedIn
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jul 2023 to Jul 2024